211 related articles for article (PubMed ID: 27626672)
1. Drosophila Cancer Models Identify Functional Differences between Ret Fusions.
Levinson S; Cagan RL
Cell Rep; 2016 Sep; 16(11):3052-3061. PubMed ID: 27626672
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
4.
Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
[TBL] [Abstract][Full Text] [Related]
5. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Dar AC; Das TK; Shokat KM; Cagan RL
Nature; 2012 Jun; 486(7401):80-4. PubMed ID: 22678283
[TBL] [Abstract][Full Text] [Related]
6. KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.
Das TK; Cagan RL
Cell Rep; 2017 Sep; 20(10):2368-2383. PubMed ID: 28877471
[TBL] [Abstract][Full Text] [Related]
7. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
Gozgit JM; Chen TH; Song Y; Wardwell S; Wang F; Cai J; Li H; Edgren H; Rivera VM; Pritchard J
Oncotarget; 2018 Jul; 9(51):29654-29664. PubMed ID: 30038711
[TBL] [Abstract][Full Text] [Related]
8. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
Laxmi A; Gupta P; Gupta J
Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
[TBL] [Abstract][Full Text] [Related]
9. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
[TBL] [Abstract][Full Text] [Related]
11. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
12. S100 and CD34 positive spindle cell tumor with prominent perivascular hyalinization and a novel NCOA4-RET fusion.
Michal M; Ptáková N; Martínek P; Gatalica Z; Kazakov DV; Michalová K; Stoláriková L; Švajdler M; Michal M
Genes Chromosomes Cancer; 2019 Sep; 58(9):680-685. PubMed ID: 30938880
[TBL] [Abstract][Full Text] [Related]
13. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
Wijesinghe P; Bepler G; Bollig-Fischer A
J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
[TBL] [Abstract][Full Text] [Related]
14. NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.
Kim SY; Oh SO; Kim K; Lee J; Kang S; Kim KM; Lee W; Kim ST; Nam DN
J Cancer; 2018; 9(17):3032-3037. PubMed ID: 30210625
[TBL] [Abstract][Full Text] [Related]
15. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
16. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
17. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
19. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M; Yang D; Lakkaniga NR; Frett B; McConnell N; Zhang L; Brescia A; Federico G; Zhang L; Salerno P; Santoro M; Li HY; Carlomagno F
Sci Rep; 2021 Aug; 11(1):16103. PubMed ID: 34373541
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
Han M; Li S; Ai J; Sheng R; Hu Y; Hu Y; Geng M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5679-5684. PubMed ID: 27815117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
